ストックスクリーナーアプリを入手
3.88
1.27%
-0.05
プレマーケット:
3.86
-0.02
-0.52%
前日終値:
$3.93
開ける：
$3.895
24時間の取引高:
1.54M
Relative Volume:
0.34
時価総額：
$473.53M
収益：
$44.55M
当期純損益:
$-83.78M
株価収益率:
-4.991
EPS:
-0.7774
ネットキャッシュフロー:
$-52.99M
1週間 パフォーマンス:
-5.60%
1か月 パフォーマンス:
-5.13%
6か月 パフォーマンス:
-28.41%
1年 パフォーマンス:
+19.38%
1日の値動き範囲:
$3.7664
$3.91
1週間の範囲:
$3.7664
$4.17
52週間の値動き範囲:
$2.12
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
名前
Aquestive Therapeutics Inc
セクター
電話
908-941-1900
住所
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.88 | 473.53M | 44.55M | -83.78M | -52.99M | -0.7774 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 開始されました | Leerink Partners | Outperform |
| 2024-04-11 | 開始されました | Piper Sandler | Overweight |
| 2024-03-28 | 開始されました | Raymond James | Outperform |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2019-04-22 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-03 | 開始されました | Lake Street | Buy |
| 2018-08-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2018-08-20 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aquestive Therapeutics Inc (AQST) 最新ニュース
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST - ChartMill
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Claims CEO Allegedly Misrepresented Company Prospects: Levi & Korsinsky - Business Wire
AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities - GuruFocus
AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Robbins LLP Urges AQST Stockholders Who Lost Money Investing in Aquestive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action - Morningstar
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. - GlobeNewswire
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges Aquestive - GlobeNewswire
Aquestive Therapeutics appoints Zalewski to chief legal officer and chief compliance officer - ROI-NJ
AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026 - Sahm
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit - ChartMill
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to ... - Caledonian Record
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST - GlobeNewswire Inc.
Lake Street adjusts Aquestive Therapeutics, Inc. (AQST) valuation model on expected approval delay - MSN
Published on: 2026-03-22 06:39:45 - baoquankhu1.vn
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2025 earnings call transcript - MSN
Aquestive Therapeutics Announces Key Legal Leadership Transition - The Globe and Mail
Aquestive names Thomas Zalewski as chief legal officer - Investing.com
Aquestive Therapeutics Names New Chief Legal, Compliance Officer - Bloomberg Law News
Aquestive Therapeutics Appoints Thomas A. Zalewski as Chief Legal Officer, Succeeding Lori J. Braender 7 - Minichart
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AQST Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Aquestive Therapeutics Appoints Thomas A. Zalewski as Chief Legal & Compliance Officer - citybiz
Aquestive names Thomas Zalewski as chief legal officer By Investing.com - Investing.com Canada
Aquestive (NASDAQ: AQST) reshapes legal team with new CLO and equity grants - Stock Titan
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer - The Manila Times
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. ... - Caledonian Record
AQST Stock Price, Quote & Chart | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aquestive - GlobeNewswire
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Aquestive plans 75-rep Anaphylm launch and targets $46M–$50M in 2026 revenue while doubling medical affairs - MSN
Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. Investors - GlobeNewswire
AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive ... - Bluefield Daily Telegraph
AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT - GlobeNewswire
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AQST CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
Volume Recap: Can Aquestive Therapeutics Inc grow without external fundingTrade Ideas & Verified Swing Trading Watchlist - baoquankhu1.vn
Aquestive Therapeutics Faces Investor Lawsuit Over Alleged FDA Approval Misrepresentations for Anaphylm - TipRanks
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm – Company AnnouncementFT.com - Financial Times
ROSEN Law Firm Encourages Aquestive Therapeutics Investors to Seek Counsel Before Deadline - National Today
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure ... - Caledonian Record
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Aquestive - GlobeNewswire
AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026 - PR Newswire
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Aquestive Therapeutics Maps Risky Path to ANNAFILM Launch - TipRanks
Aquestive Therapeutics Inc (AQST) 財務データ
収益
当期純利益
現金流量
EPS
1.75%
1.88%
大文字化:
|
ボリューム (24 時間):